

FILE

Dkt. 2048/57906-B/JPW/MAF/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : William Olson and Paul Maddon

Serial No. : 09/594,983

Examiner: Shannon A. Foley

Filed : June 15, 2000

Group Art Unit: 1648

For : SYNERGISTIC INHIBITION OF HIV-1 FUSION AND  
ATTACHMENT, COMPOSITIONS AND ANTIBODIES THERETO1185 Avenue of the Americas  
New York, NY 10036  
September 3, 2003Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In compliance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references, which are listed on the accompanying form PTO-1449 (Exhibit A).

1. Co, et al., "Humanized Antibodies for Antiviral Therapy", Proceedings of the National Academy of Science, USA, April 1991, Vol. 88, pages 2869-2873.
2. Trkola, et al., "Potent Broad-spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140", Journal of Virology, January 2001, Vol. 75, No. 2, pages 579-588.
3. Olson, et al., "Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, Gp 120 binding and CC-chemokine Activity of Monoclonal Antibodies to

Applicants: William Olson and Paul Maddon

Serial No.: 09/594,983

Filed: June 15, 2000

Page 2

CCR5", Journal of Virology, May 1999, Vol. 73, No. 5, pages 4145-4155.

4. Parren, et al., "Antibody Protects Macaques Against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro", Journal of Virology, Vol. 75, No. 17, pages 8340-8347.
5. Lehner, et al., "Immunogenicity of the Extracellular Domains of C-C Chemokine Receptor 5 and the In Vitro Effects on Simian Immunodeficiency or HIV Infectivity", Journal of Immunology, January 2001, Vol. 166, No. 12, pages 7446-7455.
6. Wu, et al., "CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophagetropic HIV-1 in Vitro", Journal of Experimental Medicine, May 5, 1997, Vol. 185, No. 9, pages 1681-1691.

The subject application is a continuation-in-part of and claims benefit under 35 U.S.C. § 120 of U.S. Serial No. 09/464,902, filed December 16, 1999. Copies of references 1-6 listed above were submitted to the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement on September 3, 2003 in connection with U.S. Serial No. 09/464,902. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

None of the above references are believed to teach or suggest the presently claimed invention, whether taken alone or in combination with any other cited reference(s).


Serial No.: 097594,983

Filed: June 15, 2000


Page 4

A fee of \$180.00 is believed due under 37 C.F.R. §1.97(d)(2) for submission of this Supplemental Information Disclosure Statement and a check for the subject amount is included herewith. If any additional fee is required, authorization is herewith provided to charge the fee concerning this matter to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Mark A. Farley  
Registration No. 33,170  
Attorneys for Applicants  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:	
Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450	
	Date <u>9/3/03</u>
John P. White	
Reg. No. 28,678	
Mark A. Farley	
Reg. No. 33,170	